Literature DB >> 20393871

Stability and biodistribution of a biodegradable macromolecular MRI contrast agent Gd-DTPA cystamine copolymers (GDCC) in rats.

Xueming Wu1, Yuda Zong, Zhen Ye, Zheng-Rong Lu.   

Abstract

PURPOSE: The aim of this study was to evaluate stability and Gd tissue distribution of a biodegradable macromolecular MRI contrast agent, GDCC.
METHODS: Kinetic stability of GDCC was evaluated based on transmetallation with endogenous metal ions Zn2+ and Cu2+ in rat plasma in comparison with Omniscan, MultiHance and ProHance. In vivo transmetallation of GDCC was evaluated by determining metal content in the urine samples of Spague-Dawley rats. The biodistribution of the agents was determined in rats at 48 h post-injection.
RESULTS: A new method of using ultrafiltration was developed for study of kinetic stability against transmetallation of Gd(III)-based MRI contrast agents. Both in vitro and in vivo stability of the contrast agents towards transmetallation with Zn2+ were in the order of ProHance > MultiHance approximately GDCC > Omniscan. No significant transmetallation with Cu2+ was observed for the contrast agents. GDCC had comparable retention to the control agents in most organs and tissues with slightly high retention in the liver and kidneys at 48 h post-injection.
CONCLUSION: Ultrafiltration is efficient and accurate for characterizing the kinetic stability of Gd(III)-based MRI contrast agents. The novel biodegradable macromolecular contrast agent GDCC is promising for further development for contrast enhanced MRI.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20393871      PMCID: PMC3025703          DOI: 10.1007/s11095-010-0131-9

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  26 in total

1.  Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition?

Authors:  S K Morcos
Journal:  Br J Radiol       Date:  2007-03-28       Impact factor: 3.039

2.  Nephrogenic systemic fibrosis, kidney disease, and gadolinium: is there a link?

Authors:  Mark A Perazella
Journal:  Clin J Am Soc Nephrol       Date:  2007-02-07       Impact factor: 8.237

Review 3.  Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy).

Authors:  Anjela Galan; Shawn E Cowper; Richard Bucala
Journal:  Curr Opin Rheumatol       Date:  2006-11       Impact factor: 5.006

Review 4.  Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review.

Authors:  Jean-Marc Idée; Marc Port; Isabelle Raynal; Michel Schaefer; Soizic Le Greneur; Claire Corot
Journal:  Fundam Clin Pharmacol       Date:  2006-12       Impact factor: 2.748

5.  Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review.

Authors:  Marc Port; Jean-Marc Idée; Christelle Medina; Caroline Robic; Monique Sabatou; Claire Corot
Journal:  Biometals       Date:  2008-03-15       Impact factor: 2.949

6.  Contrast-enhanced MRI-guided photodynamic cancer therapy with a pegylated bifunctional polymer conjugate.

Authors:  Anagha Vaidya; Yongen Sun; Yi Feng; Lyska Emerson; Eun-Kee Jeong; Zheng-Rong Lu
Journal:  Pharm Res       Date:  2008-06-27       Impact factor: 4.200

7.  A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media.

Authors:  Martin A Sieber; Hubertus Pietsch; Jakob Walter; Wolfram Haider; Thomas Frenzel; Hanns-Joachim Weinmann
Journal:  Invest Radiol       Date:  2008-01       Impact factor: 6.016

8.  Gadolinium-based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: the role of excess ligand.

Authors:  Martin A Sieber; Philipp Lengsfeld; Jakob Walter; Heiko Schirmer; Thomas Frenzel; Fred Siegmund; Hanns-Joachim Weinmann; Hubertus Pietsch
Journal:  J Magn Reson Imaging       Date:  2008-05       Impact factor: 4.813

9.  Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions.

Authors:  Martin A Sieber; Philipp Lengsfeld; Thomas Frenzel; Sven Golfier; Heribert Schmitt-Willich; Fred Siegmund; Jakob Walter; Hanns-Joachim Weinmann; Hubertus Pietsch
Journal:  Eur Radiol       Date:  2008-06-11       Impact factor: 5.315

10.  Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure--role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate.

Authors:  Preethi Yerram; Georges Saab; Poorna R Karuparthi; Melvin R Hayden; Ramesh Khanna
Journal:  Clin J Am Soc Nephrol       Date:  2007-02-07       Impact factor: 8.237

View more
  10 in total

1.  Synthesis and evaluation of a peptide targeted small molecular Gd-DOTA monoamide conjugate for MR molecular imaging of prostate cancer.

Authors:  Xueming Wu; Susan M Burden-Gulley; Guan-Ping Yu; Mingqian Tan; Daniel Lindner; Susann M Brady-Kalnay; Zheng-Rong Lu
Journal:  Bioconjug Chem       Date:  2012-08-01       Impact factor: 4.774

2.  Molecular MRI of atherosclerotic plaque progression in an ApoE(-/-) mouse model with a CLT1 peptide targeted macrocyclic Gd(III) chelate.

Authors:  Xueming Wu; Niranjan Balu; Wen Li; Yong Chen; Xiaoyue Shi; China M Kummitha; Xin Yu; Chun Yuan; Zheng-Rong Lu
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-09-19

3.  An effective targeted nanoglobular manganese(II) chelate conjugate for magnetic resonance molecular imaging of tumor extracellular matrix.

Authors:  Mingqian Tan; Xueming Wu; Eun-Kee Jeong; Qianjin Chen; Dennis L Parker; Zheng-Rong Lu
Journal:  Mol Pharm       Date:  2010-08-02       Impact factor: 4.939

4.  Cationic gadolinium chelate for magnetic resonance imaging of cartilaginous defects.

Authors:  Kido Nwe; Ching-Hui Huang; Feini Qu; Robert Warden-Rothman; Clare Y Zhang; Robert L Mauck; Andrew Tsourkas
Journal:  Contrast Media Mol Imaging       Date:  2016-02-08       Impact factor: 3.161

5.  A neutral polydisulfide containing Gd(III) DOTA monoamide as a redox-sensitive biodegradable macromolecular MRI contrast agent.

Authors:  Zhen Ye; Zhuxian Zhou; Nadia Ayat; Xueming Wu; Erlei Jin; Xiaoyue Shi; Zheng-Rong Lu
Journal:  Contrast Media Mol Imaging       Date:  2015-07-27       Impact factor: 3.161

6.  Gd-encapsulated carbonaceous dots with efficient renal clearance for magnetic resonance imaging.

Authors:  Hongmin Chen; Geoffrey D Wang; Wei Tang; Trever Todd; Zipeng Zhen; Chu Tsang; Khan Hekmatyar; Taku Cowger; Richard Hubbard; Weizhong Zhang; John Stickney; Baozhong Shen; Jin Xie
Journal:  Adv Mater       Date:  2014-09-01       Impact factor: 30.849

7.  Synthesis and evaluation of a polydisulfide with Gd-DOTA monoamide side chains as a biodegradable macromolecular contrast agent for MR blood pool imaging.

Authors:  Zhen Ye; Xueming Wu; Mingqian Tan; Jack Jesberger; Mark Grisworld; Zheng-Rong Lu
Journal:  Contrast Media Mol Imaging       Date:  2013 May-Jun       Impact factor: 3.161

8.  Multimodal imaging enables early detection and characterization of changes in tumor permeability of brain metastases.

Authors:  Frits Thorsen; Brett Fite; Lisa M Mahakian; Jai W Seo; Shengping Qin; Victoria Harrison; Sarah Johnson; Elizabeth Ingham; Charles Caskey; Terje Sundstrøm; Thomas J Meade; Patrick N Harter; Kai Ove Skaftnesmo; Katherine W Ferrara
Journal:  J Control Release       Date:  2013-10-29       Impact factor: 9.776

9.  Macromolecular Imaging Agents Containing Lanthanides: Can Conceptual Promise Lead to Clinical Potential?

Authors:  Joshua Bryson; Jeffrey W Reineke; Theresa M Reineke
Journal:  Macromolecules       Date:  2012-11-13       Impact factor: 5.985

10.  Excretable, ultrasmall hexagonal NaGdF4:Yb50% nanoparticles for bimodal imaging and radiosensitization.

Authors:  Jossana A Damasco; Tymish Y Ohulchanskyy; Supriya Mahajan; Guanying Chen; Ajay Singh; Hilliard L Kutscher; Haoyuan Huang; Steven G Turowski; Joseph A Spernyak; Anurag K Singh; Jonathan F Lovell; Mukund Seshadri; Paras N Prasad
Journal:  Cancer Nanotechnol       Date:  2021-02-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.